3000+ Attendees, 450 Speakers, 12 Conference Tracks, 100+ Posters
 
MMTC15_Header  
MMTC M Header 

Cambridge Healthtech Institute’s Third Annual

Companion Diagnostics

Future of Cancer Management

February 16-18, 2015 | Moscone North Convention Center | San Francisco, CA
Part of the 22nd Annual Molecular Medicine Tri-Conference

 

The field of companion diagnostics is undergoing radical changes with the battery of sequencing tests available and adoption of new clinical trial protocols. The reality is becoming apparent that a new strategy is needed for implementing and commercializing molecularly guided therapies. More personalized therapies are available but significant questions remain as to how to get patients the treatments best suited to their disease. Multi-gene panels are becoming the standard of care in oncology but the practice is far from commonplace. Practical aspects of reimbursement, regulation, patient payment responsibility, commercial launch and drug development will be covered in this comprehensive program detailing the state-of-the-art process for implementing companion diagnostics.

Scientific Advisory Board

Glenn A. Miller, Ph.D., CTO & Executive Vice President, Molecular MD

Jonathan Pan, Ph.D, MBA, Director, Oncology Companion Diagnostic and Disease Strategy, GlaxoSmithKline

John Pfeifer, M.D., Ph.D., Vice Chair for Clinical Affairs, Pathology; Professor, Pathology and Immunology; Professor, Obstetrics and Gynecology, Washington University School of Medicine

Hakan Sakul, Ph.D., Executive Director and Head, Diagnostics, Worldwide R&D, Development Operations, Pfizer, Inc.


PRACTICAL ASPECTS OF IMPLEMENTING THE MASTER PROTOCOL

Correlative Studies and Specimen Analysis in the Squamous Cell Carcinoma Master Protocol

Philip C. Mack, Ph.D., Associate Adjunct Professor, Internal Medicine, Hematology and Oncology, University of California Davis Medical Center

Match Protocol

P. Mickey Williams, Ph.D. (contractor), Director of Molecular Characterization Laboratory (MoCha), Frederick National Laboratory for Cancer Research


RNA-SEQ FOR PATIENT STRATIFICATION

Genetic Profiling of Hematologic Malignancies

Ross L. Levine, M.D., Associate Member, HOPP; Associate Attending, Leukemia Service; Memorial Sloan-Kettering Cancer Center

Sequencing Approaches for Personalized Cancer Therapy Selection and Monitoring

Daniela Starcevic, Ph.D., Director, Diagnostic Sequencing; Assistant Professor, Genomics and Multiscale Biology; Assistant Professor, Pathology; Icahn School of Medicine at Mount Sinai

Clinical Trials for Precision Oncology Using Next-Generation Sequencing

Sameek Roychowdhury, M.D., Ph.D., Assistant Professor, Internal Medicine, Medical Oncology, Pharmacology, Comprehensive Cancer Center, Ohio State University


COMMERCIALIZATION DYNAMICS OF COMPANION DIAGNOSTICS

PANEL DISCUSSION: Commercializzation Dynamics of Companion Diagnostics: One Size Does Not Fit All

Moderator: Jonathan Pan, Ph.D, MBA, Director, Oncology Companion Diagnostic and Disease Strategy, GlaxoSmithKline

Developing specs for commercial success, requirements for diagnostic standards needed, differences in the global landscape, creating commercialization models, reimbursement

  • Define commercialization requirements lead by engineering
  • R&D to commercialization interface
  • Perspective on global market

Companion Diagnostics Assessment and Approval in Ontario; Insights from a Publicly-Funded System Perspective

Suzanne Kamel-Reid, Ph.D., DABMG, FACMG, Head, Clinical Laboratory Genetics; Director, Molecular Diagnostics, Pathology, The University Health Network; The University of Toronto

Define Commercialization Requirements Lead By Engineering

Jonathan Pan, Ph.D, MBA, Director, Oncology Companion Diagnostic and Disease Strategy, GlaxoSmithKline

PANEL DISCUSSION: How the Business Model is Changing for One Drug, One Diagnostic

Moderator: Hakan Sakul, Ph.D., Executive Director and Head, Diagnostics, Worldwide R&D, Development Operations, Pfizer, Inc.

Panelist:

Sarah Byron, Ph.D., Diagnostics Assessment Program, National Institute for Health and Care Excellence

Additional Panelists to be Announced


IMPLEMENTATION STRATEGIES FOR NGS-BASED COMPANION DIAGNOSTICS

What Processes Are Needed for Using NGS as a Companion Diagnostic?

John Pfeifer, M.D., Ph.D., Vice Chair for Clinical Affairs, Pathology; Professor, Pathology and Immunology; Professor, Obstetrics and Gynecology, Washington University School of Medicine

Talk Title to be Announced

Dane J. Dickson, M.D., Director, Clinical Science, MolDx, Palmetto GBA


CTCs FOR COMPANION DX

CTCs in Mouse Models

Jen Jen Yeh, M.D., Associate Professor, Surgery and Pharmacology, UNC Chapel Hill Lineberger Comprehensive Cancer Center

Challenges and Opportunities in the Use of CTCs for Companion Diagnostic Development

Elizabeth Punnoose, Ph.D., Oncology Biomarker Development, Genentech, Inc.

Additional Presentation


Additional Presentation



For more details on the conference, please contact:
Christina Lingham
Executive Director, Conferences
Cambridge Healthtech Institute
T: 781-972-5464
E: clingham@healthtech.com 

For partnering and sponsorship information, please contact:
Jon Stroup (Companies A-K)
Manager, Business Development
Cambridge Healthtech Institute
T: (+1) 781-972-5483
E: jstroup@healthtech.com 

Joseph Vacca (Companies L-Z) 
Manager, Business Development
Cambridge Healthtech Institute
T: (+1) 781.972.5431
E: jvacca@healthtech.com
 

 


  2015 Plenary Sessions 


2015 MMTC Prelim Agenda 

Premier Sponsors:

 

Jackson Laboratory - small logo 

Leica Biosystems 
 

 NanoString2   

 

Singulex